News and events

A study led by Anne Hege Aamodt, head of the "Stroke, headache and covid research group" at the Department of Neurology and cardiologist Dan Atar has shown that atrial fibrillation is the hidden cause of stroke in many patients, and that long-term heart rhythm monitoring of patients can prevent recurrent strokes in this group.
The results are presented in the European Stroke Journal. The findings have been summarized in a news article on sciencenorway.no, the English version of the award-winning popular science web site forskning.no, and presented via major Norwegian news outlets.

Brain Health perspectives and lifestyle was the topic The Norwegian Research Days - "Forskningsdagene" - at Lillestrøm Innovation Centre the September 30^th with Aamodt as lecturer.

Aamodt is part of the CHARGE Consortium and a co-author of the paper:

Stroke genetics informs drug discovery and risk prediction across ancestries
Aniket Mishra, Rainer Malik, Tsuyoshi Hachiya, Tuuli Jürgenson, Shinichi Namba, Daniel C. Posner, et al.
Nature. 2022 Sep 30:1-15. doi: 10.1038/s41586-022-05165-3. 
PMID: 36180795

On the 22nd of September the moyamoya team at Oslo University Hospital arranged a course for patients with moyamoy and ther next-of-kin. In 2021 Aamodt got grants from Through a pilot project with previous grants from Dam and Odd Fellow to a quality project in moyamoya. In cooperation with the user organisation Norwegian Heart and Lung Patient Association and our user panel at the Division of Clinical Neuroscience, Oslo University Hospital, we have streamlined the workflow with a structured «one-door-in» strategy and state of the art diagnostic work-up for treatment and follow-up of moyamoya patients in Norway. We have established courses led by the moyamoya team and user representatives covering central topics including information on disease and treatment, coping strategies, lifestyle factors and networking platforms for patients and next-of-kin.

TenCRAOS started in Stavanger. Aamodt led the start-up meeting at Stavanger University Hospital – the last hospital in Norway to be activated. The trial has now 26 active sites with 18 of 78 patients included in the trial.

The TenCRAO trial presented at the 22^nd Euretina Congress in Hamburg - EURETINA – European Society of Retina Specialists. Aamodt was invited by the organizer to present the trial at the congress during the research session.

https://euretina.org/resource/euretina-session-research-session-2/ 

The Norwegian Centre for Headache Research (NorHEAD) in Trondheim was opened the on 1^st of September and will carry out world-leading research on headache disorders. NorHEAD is a Centre for Clinical Treatment Research, funded by the Research Council of Norway. NorHEAD will. The goal is to systematize and improve current treatment knowledge and develop new and innovative therapies for the benefit of patients suffering from headache disorders. Oslo University Hospital is a partner in NorHEAD and several of the headache studies led from Oslo, such as the CovaxHEAD study, is under the NorHEAD umbrella. Aamodt has a part-time position at the Norwegian University of Science and Technology and is the chair of the Scientific Advisory board with 4 leading international professors. 

The Norwegian Headache Research Centre will have the formal opening the 1st of September.

Aamodt is the Chair of the Scientific Advisory Board of NorHEAD – the Norwegian Headache Research Centre - and is from the 1st of August 2022 affiliated to NTNU. 

NorHEAD is a Centre for Clinical Treatment Research funded by the Research Council of Norway. NorHEAD will carry out world-leading research on headache disorders with the goal to systematize and improve current treatment knowledge, and develop new and innovative therapies for the benefit of patients suffering from headache disorders.

Many useful and inspiring meeting places and debate arenas during Arendalsuka, 15-19.8 2022.

The Norwegian centres participate in the ENERGY register. 
The data are delivered from Prjcts Ledidi in the Norwegian NeuroCovid study, led by Aamodt.

More information on ENERGY

Results from the Norwegian NeuroCovid Study led by Anne Hege Aamodt were presented at the EAN Congress in Vienna by postdoc Marion Boldingh, Department of Neurology, Oslo University Hospital.

The TenCRAOS trial is recruiting steadily new centres and have follow-up meetings with the activated centres heading for more inclusions.

Meetings with Belgian centres Antwerpen, Erasme, Leuven and Brussels, the Danish centres Bispebjerg University Hospital and Aarhus, Bergen and Kristiansand, the Austrian lead, dr. Slaven Pikija at Kristian Doppler University Hospital in Salzburg and the national lead in Lithuania, Associate Professor Jurgita Valaikiene have recently been arranged.

On 5 April, the 6th national meeting on endovascular intervention in acute cerebral infarction was organized in the Runde auditorium at Domus Medica with OUS and UiO as hosts. A number of OUS employees contributed with lectures in addition to contributions from other Norwegian thrombectomy centers and neurology professor Bruce Campbell from Melbourne, Australia.

The Norwegian Stroke Association and the Norwegian Neuroradiology Association are behind the meetings, which have been organized annually since the Year of the Brain 2015 with Anne Hege Aamodt as the prime mover. In addition, Rajiv Advani, Mona Skjelland, Christian Lund, Else Charlotte Sandset, Stephen J. Ryan, Brian Enriquez and neuroradiologist Terje Nome and anesthetist from OUS and Marianne Altmann from Ahus participated in the event committee.

It was the first physical meeting since the start of the pandemic and with the good help of IT in the Medical Association, the meeting was organized as a hybrid.

The topline results of the Nordic Atrial Fibrillation and Stroke Study (NOR-FIB) presented at the Annual congress of the European Heart Rhythm Association – EHRA in Copenhagen on 4th of April 2022 and at the European Stroke Organisation Conference in Lyon on the 4th of May 2022 by senior consultant and PhD student Barbara Ratajczak-Tretel.

Anne Hege Aamodt er tildelt Formidlingsprisen 2022 fra Norsk nevrologisk forening for sitt formidable arbeid med å fremme norsk nevrologi både nasjonalt og internasjonalt.

Les saken fra hjemmesiden til Norsk nevrologisk forening:
Formidlingsprisen 2022 gikk til Anne Hege Aamodt

Oppdatering om hjernehelse, korona og den norske nevrocovid-studien på NRK P1 Pluss.

Prosjektleder Anne Hege Aamodt var invitert som frokostgjest 11. januar 2022 for å fortelle om nevrologiske komplikasjoner ved covid-19 og den norske nevrocovid-studien.

Programinformasjon
De fleste som blir rammet av Covid-19 blir kvitt symptomene raskt, men noen pasienter kan få langvarige nevrologiske skader. Gjest: Anne Hege Aamodt 
Link til sendingen (11.01.2022 · 1 t 55 min)

Mens en av tre får hjernerelaterte symptomer i akuttfasen ved covid-19, har hver tiende symptomer mer enn tre måneder etter å ha hatt covid-19. Hos mange av dem er nevrologiske manifestasjoner en vesentlig forklaring.

Link til artikkelen:
Hver tiende får langvarige plager etter covid-19 (Nevrologisk Tidsskrift, 24.01.2022)

Teamet i Oslo som er vist under var en av vinnerne av Christmas Challenge i denne internasjonale multisenterstudien som undersøker effekten av trombektomi av store hjerneinfarkter.

Studien ledes fra Heidelberg og foregår i en rekke land i Europa og Canada. Anne Hege Aamodt er nasjonal leder av studien i Norge og PI ved OUS.

The NOR-FIB study is presented at two sessions during ESOC with new data from the biomarker study and updated data on the inclusion of participants. Many of the investigators participated at the Investigator meeting during the first day of the congress.

Anne Hege Aamodt, manager of ECRI, was during the EAN conference given the "EAN Investigator Award 2018" for her presentasjonen entitled "Effect and safety of tenecteplase in stroke patients with atrial fibrillation".

Investigator Award Winners 2018

EAN congress Lisbon 2018 homepage

Anne Hege Aamodt was invited speaker at the European Stroke Organisation Congress in Gothenburg in May to talk about treatment in Central Retinal Artery Occlusion and presented at new planned international randomised controlled trial with tenecteplase - the TEN-CRAOS Study.
The NOR-FIB study was also presented at ESOC by PhD student Anna T. Lambert and there was an Investigator meeting with participants from all Scandinavian countries.

Media coverage (collection of links from legeforeningen.no)

On 23/11-2017 we held an open meeting on stroke at Oslo University Hospital. There was great support for the meeting and many who attended. We thank everyone who attended the meeting.
Some of the presentations will be posted after the meeting.